Bayesian interpretation of immunotherapy trials with dynamic treatment effects

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer

(2020) D. Planchard et al.   ANNALS OF ONCOLOGY

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

(2020) Markus H. Moehler et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

(2020) R.L. Ferris et al.   ANNALS OF ONCOLOGY

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

(2020) Naiyer A. Rizvi et al.   JAMA Oncology

Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings

(2020) Eduardo Castañon et al.   EUROPEAN JOURNAL OF CANCER

BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time‐to‐event efficacy

(2020) Beibei Guo et al.   STATISTICS IN MEDICINE

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors and Implications

(2019) Rifaquat M Rahman et al.   CLINICAL CANCER RESEARCH

Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients with Septic Shock: A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial

(2019) Fernando G Zampieri et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis

(2019) Ray S. Lin et al.   Statistics in Biopharmaceutical Research

The Cancer Immunotherapy Revolution

(2018) Priscilla N. Kelly   SCIENCE

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with

(2018) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

(2018) M Reck et al.   ANNALS OF ONCOLOGY

brms: An R Package for Bayesian Multilevel Models Using Stan

(2017) Paul-Christian Bürkner   Journal of Statistical Software

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Bayesian dynamic regression models for interval censored survival data with application to children dental health

(2013) Xiaojing Wang et al.   LIFETIME DATA ANALYSIS

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Why Do Phase III Clinical Trials in Oncology Fail so Often?

(2012) L. Amiri-Kordestani et al.   JNCI-Journal of the National Cancer Institute

Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials

(2008) Duminda N. Wijeysundera et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY